Orexigen Therapeutics, Inc.
Also known as
- Orexigen
OREXIGEN™ Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system disorders, with an initial focus on obesity. OREXIGEN’s lead combination product candidates targeted for obesity are Contrave™, which is in a Phase III clinical trial, and Empatic™ (formerly Excalia™), which is in a Phase IIb clinical trial.
Business
| Date founded |
| Place founded |
| Headquarters |
|
street address
|
city/town
|
state/province/region
|
postal code
|
country
|
|---|---|---|---|---|
|
| |||
| Legal structure |
| Industry |
| Revenue |
| Operating income |
| Market capitalization |
| Founders |
| Net income |
| Board members |
|
member
|
title
|
from
|
|---|---|---|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Major shareholders |
| Advisors |
| Number of employees |
| Ticker symbol |
|
stock exchange
|
ticker symbol
|
|---|---|
|
|
| Slogan |
| Previous names |
| Parent company |
| Subsidiary companies |
| Spun off from |
| Spin offs |
| Acquired by |
| Companies acquired |
| Involved in merger |
| Product of merger |
| Business Locations |
| Divisions |
| Employees and other personnel |
|
person
|
title
|
from
|
|---|---|---|
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
|
||
With the exception of Wikipedia summaries and some images the
content on this page is typically distributed under
the Creative Commons
Attribution license or Public Domain.
| Gallery | add an image | edit gallery |
Recent Discussions about Orexigen Therapeutics, Inc.
There are no conversations on this topic. Would you like to start one?
Start the Discussion